What is the best dose of aspirin in association with P2Y12 antagonists?

Heart

Volumn 97, Issue 3, 2011, Pages 263-264

  Cattaneo, Marco ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PROSTACYCLIN; PURINERGIC P2Y12 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; THROMBOXANE A2; TICAGRELOR;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; LETTER; LOW DRUG DOSE; MONOTHERAPY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; THROMBOGENESIS; THROMBOSIS;

ASPIRIN; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS;

EID: 78651225994     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2010.216812     Document Type: Letter

References (4)

1. Warner TD, Armstrong PCJ, Curzen NP, et al. Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists? Heart 2010;96:1693-4.
2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-60.
3. Cattaneo M, Lecchi A. Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin. J Thromb Haemost 2007;5:577-82.
4. CURRENT-OASIS 7 Investigators, Mehta SR, Bassand JP, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010;363:930-42.